接受氟尿嘧啶联合亚叶酸方案治疗或是吉西他滨方案治疗患者的中位生存期分别为23.0个月及23.6个月。
Median survival for patients treated with fluorouracil plus folinic acid was 23.0 months and for patients treated with gemcitabine was 23.6 months.
在治疗结束时，蛋白酶体水平升高患者的中位生存期是30.2个月。蛋白酶体水平恢复正常的患者没有观察到终点事件。
Median survival at the end of treatment was 30.2 months in patients with elevated levels. This point was not reached in patients with normalized levels.
血浆中egfr外显子19删除患者的中位生存期要明显好于那些存在L 858r变异患者(32个月相对14个月)。
Median survival time for patients with an EGFR exon 19 deletion in serum was also substantially higher than in those with L858R mutations (32 months vs 14 months).
对124名法国患者的进一步研究提示，运用该模型，认为无风险的患者中位生存期为378天，有风险的只有90天。
Study of a further 124 French patients showed that those deemed at good risk using the model, had a median survival of 378 days, compared to 90 days in the poor risk group.
吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
应用推荐